Contributions
Abstract: EP1616
Type: ePoster
Abstract Category: Pathology and pathogenesis of MS - 25 Biomarkers
Background: Despite the establishment of some well-known factors invloved in MS pathology, no specific biomarker of the disease is currently available. The cerebrospinal fluid (CSF) metabolome, defined as the set of all CSF metabolites might be important for MS diagnosis and management.
Goals: To assess differences in the CSF metabolite profiles between
relapsing-remitting MS patients (RRMS) and healthy controls (HCs) according to the presence of active inflammatory plaques in the brain or cervical spinal cord on magnetic resonance imaging (MRI).
Methods: 14 RRMS patients and 12 HCs were included in the study. Patients were divided into 2 groups: MS-I group: 6 patients without disease modyfing therapy (DMT) who showed active inflammatory plaques in the brain or cervical spinal cord on MRI and 8 MS patients lacking such plaques on MRI (MS-II group). To evaluate metabolome of CSF, 1H NMR spectroscopy was used. The comparison of metabolic profile between MS-I, MS-II and HCs was conducted and the pathway analysis was performed.
Results: The CSF metabolome did not significantly differ between MS patients and HCs (R2Y=0.09, Q2Y=-0.17 - single-component score; permutation test statistic for separation distance: p=0.46). The results of partial least square discriminant analysis (PLS-DA) indicated significant discrimination between the MS-I group and the MS-II group (R2Y=0.70, Q2Y=0.56 - single-component model; permutation test statistic for separation distance: p=0.024). The variables predominantly responsible for the distinction between the MS-I and MS-II groups were spectral regions corresponding to lactate, creatine, L-glutamine, acetic acid, and D-glucose which revealed that concentrations of the identified metabolites were used to perform enrichment analysis that revealed that changes in CSF metabolite profiles in MS patients with active plaques on MRI primarily affected the pyruvate metabolism pathway.
Conclusions: Distinct metabolite profiles between RRMS patients with and without active inflammatory plaques in the brain or cervical spinal cord on MRI was found. The CSF metabolome was comparable between healthy individuals and MS patients which suggests that the metabolite profile is altered only during active MS processes. 1H NMR spectroscopy is an analytical tool for metabolome determination and seems to be helpful in MS biomarker estimation.
Disclosure:
Natalia Niedziela: nothing to disclose
Kamila Osadnik: nothing to disclose
Tadeusz Osadnik: nothing to disclose
Janusz Kasperczyk: nothing to disclose
Katarzyna Kubicka-Bączyk: nothing to disclose
Monika Adamczyk-Sowa: nothing to disclose
Abstract: EP1616
Type: ePoster
Abstract Category: Pathology and pathogenesis of MS - 25 Biomarkers
Background: Despite the establishment of some well-known factors invloved in MS pathology, no specific biomarker of the disease is currently available. The cerebrospinal fluid (CSF) metabolome, defined as the set of all CSF metabolites might be important for MS diagnosis and management.
Goals: To assess differences in the CSF metabolite profiles between
relapsing-remitting MS patients (RRMS) and healthy controls (HCs) according to the presence of active inflammatory plaques in the brain or cervical spinal cord on magnetic resonance imaging (MRI).
Methods: 14 RRMS patients and 12 HCs were included in the study. Patients were divided into 2 groups: MS-I group: 6 patients without disease modyfing therapy (DMT) who showed active inflammatory plaques in the brain or cervical spinal cord on MRI and 8 MS patients lacking such plaques on MRI (MS-II group). To evaluate metabolome of CSF, 1H NMR spectroscopy was used. The comparison of metabolic profile between MS-I, MS-II and HCs was conducted and the pathway analysis was performed.
Results: The CSF metabolome did not significantly differ between MS patients and HCs (R2Y=0.09, Q2Y=-0.17 - single-component score; permutation test statistic for separation distance: p=0.46). The results of partial least square discriminant analysis (PLS-DA) indicated significant discrimination between the MS-I group and the MS-II group (R2Y=0.70, Q2Y=0.56 - single-component model; permutation test statistic for separation distance: p=0.024). The variables predominantly responsible for the distinction between the MS-I and MS-II groups were spectral regions corresponding to lactate, creatine, L-glutamine, acetic acid, and D-glucose which revealed that concentrations of the identified metabolites were used to perform enrichment analysis that revealed that changes in CSF metabolite profiles in MS patients with active plaques on MRI primarily affected the pyruvate metabolism pathway.
Conclusions: Distinct metabolite profiles between RRMS patients with and without active inflammatory plaques in the brain or cervical spinal cord on MRI was found. The CSF metabolome was comparable between healthy individuals and MS patients which suggests that the metabolite profile is altered only during active MS processes. 1H NMR spectroscopy is an analytical tool for metabolome determination and seems to be helpful in MS biomarker estimation.
Disclosure:
Natalia Niedziela: nothing to disclose
Kamila Osadnik: nothing to disclose
Tadeusz Osadnik: nothing to disclose
Janusz Kasperczyk: nothing to disclose
Katarzyna Kubicka-Bączyk: nothing to disclose
Monika Adamczyk-Sowa: nothing to disclose